WFRF:(Langdahl Bente L.)
Search: WFRF:(Langdahl Bente L.) > (2016) > Fracture Rate, Qual...
- 1 of 1
- Previous record
- Next record
- To hitlist
- Langdahl, Bente L. (author)
Fracture Rate, Quality of Life and Back Pain in Patients with Osteoporosis Treated with Teriparatide 24-Month Results from the Extended Forsteo Observational Study (ExFOS)
- E-article/E-chapterEnglish2016
Publisher, publication year, extent ...
- 2016
Numbers
- LIBRIS-ID:20187407
- http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-303024uri
- urn:nbn:se:uu:diva-303024urn
- 10.1007/s00223-016-0143-5doi
Supplementary language notes
- Language:English
Part of subdatabase
Notes
- Published
- gratis
- We describe the pre-planned interim analysis of fracture outcomes, health-related quality of life (HRQoL) and back pain in patients with severe osteoporosis treated with teriparatide for up to 24 months in the Extended Forsteo (Forsteo(A (R)) is a registered trade name of Eli Lilly and Company) Observational Study (ExFOS), a prospective, multinational, observational study. Data on incident clinical fractures, HRQoL (EQ-5D questionnaire) and back pain [100 mm visual analogue scale (VAS)] were collected. The number of patients with fractures was summarised in 6-month intervals and fracture rate over each 6-month period was assessed using logistic regression for repeated measures. Changes from baseline in EQ-5D and back pain VAS were analysed using mixed models for repeated measures. Of 1454 patients in the active treatment cohort, 90.6 % were female and 14.4 % were taking glucocorticoids. During teriparatide treatment (median duration 23.7 months), 103 patients (7.1 %) sustained a total of 122 incident clinical fractures (21 % vertebral, 79 % non-vertebral). A 49 % decrease in the odds of fractures and a 75 % decrease in the odds of clinical vertebral fractures were observed in the > 18- to 24-month period versus the first 6-month period (both p < 0.05). EQ-5D scores and back pain VAS scores were significantly improved from baseline at each post-baseline observation during teriparatide treatment. In conclusion, patients with severe osteoporosis showed a significant reduction in the incident fracture rate during 24 months of teriparatide treatment in routine clinical practice, accompanied by a significant improvement in HRQoL and reduction in back pain. Results should be interpreted in the context of the non-controlled design of this observational study.
Subject headings and genre
- Medical and Health Sciences hsv
- Clinical Medicine hsv
- Endocrinology and Diabetes hsv
- Medicin och hälsovetenskap hsv
- Klinisk medicin hsv
- Endokrinologi och diabetes hsv
- Osteoporosis
- Observational study
- Teriparatide
- Fractures
- Quality of life
- Back pain
Added entries (persons, corporate bodies, meetings, titles ...)
- Ljunggren, Östen (author)
- Benhamou, Claude-Laurent (author)
- Marin, Fernando (author)
- Kapetanos, George (author)
- Kocjan, Tomaz (author)
- Lespessailles, Eric (author)
- Napoli, Nicola (author)
- Nikolic, Tatjana (author)
- Petto, Helmut (author)
- Moll, Thomas (author)
- Lindh, Erik (author)
- Uppsala universitetMedicinska och farmaceutiska vetenskapsområdet (publisher)
Related titles
- Part of/supplement to:channel record
- In:VärdpublikationCalcified Tissue International99:3, 259-2710171-967X
Internet link
Find in a library
- Calcified Tissue International (Search for host publication in LIBRIS)
To the university's database
- 1 of 1
- Previous record
- Next record
- To hitlist
Search outside SwePub
- Extend your search to:
- Google Book Search
- Google Scholar
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
- Copyright © LIBRIS - National Library Systems
- LIBRIS.kb.se
